SCHEMBL18170844

SCHEMBL18170844

Cc1ccc(-c2ccc(NC(=O)c3ccccc3)c3c2CNC3=O)c(C)c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 7/20 0.65
KCNMA1 Q12791 1/20 0.47
CSF1R P07333 2/20 0.46
PLK4 O00444 1/20 0.46
AURKA O14965 1/20 0.46
ROCK2 O75116 1/20 0.46
MAP4K4 O95819 1/20 0.46
ABL1 P00519 1/20 0.46
NTRK1 P04629 1/20 0.46
LCK P06239 1/20 0.46
CDK1 P06493 1/20 0.46
LYN P07948 1/20 0.46
RET P07949 1/20 0.46
MET P08581 1/20 0.46
ROS1 P08922 1/20 0.46
FGFR1 P11362 1/20 0.46
FLT1 P17948 1/20 0.46
RPS6KB1 P23443 1/20 0.46
EPHA2 P29317 1/20 0.46
AXL P30530 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18170971 0.92 KDR (0.64) KDRKCNMA1CASP3CYP1A2MAPT
SCHEMBL18171022 0.91 KDR (0.62) KDRKCNMA1CSF1RPLK4AURKA
SCHEMBL18171021 0.88 KDR (0.75) KDRKCNMA1CSF1RPLK4AURKA
SCHEMBL18170622 0.87 KDR (0.71) KDRKCNMA1CSF1RPLK4AURKA
SCHEMBL18170958 0.86 KDR (0.64) KDRKCNMA1CASP3CYP1A2MAPT
SCHEMBL18170878 0.86 KDR (0.61) KDRCSF1RPLK4AURKAROCK2
SCHEMBL18170853 0.86 KDR (0.75) KDRKCNMA1CSF1RPLK4AURKA
SCHEMBL18170569 0.85 KDR (0.69) KDRKCNMA1CSF1RPLK4AURKA
SCHEMBL18170637 0.85 KDR (0.68) KDRROCK2MAP4K4LCKRET
SCHEMBL18170742 0.85 KDR (0.59) KDRKCNMA1CASP3CYP1A2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9856216-B2 Compounds as TNIK, IKKε and TBK1 inhibitors and pharmaceutical composition comprising same GREEN CROSS CORPORATION (KR) 2018-01-02 US claimed
US-20160311772-A1 COMPOUNDS AS TNIK, IKKEPSILON AND TBK1 INHIBITORS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME GREEN CROSS CORPORATION (KR) 2016-10-27 US claimed
US-9856216-B2 Compounds as TNIK, IKKε and TBK1 inhibitors and pharmaceutical composition comprising same GREEN CROSS CORPORATION (KR) 2018-01-02 US disclosed
US-9856216-B2 Compounds as TNIK, IKKε and TBK1 inhibitors and pharmaceutical composition comprising same GREEN CROSS CORPORATION (KR) 2018-01-02 US disclosed
US-20160311772-A1 COMPOUNDS AS TNIK, IKKEPSILON AND TBK1 INHIBITORS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME GREEN CROSS CORPORATION (KR) 2016-10-27 US disclosed
US-20160311772-A1 COMPOUNDS AS TNIK, IKKEPSILON AND TBK1 INHIBITORS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME GREEN CROSS CORPORATION (KR) 2016-10-27 US disclosed
US-20160311772-A1 COMPOUNDS AS TNIK, IKKEPSILON AND TBK1 INHIBITORS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME GREEN CROSS CORPORATION (KR) 2016-10-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160311772-A1 COMPOUNDS AS TNIK, IKKEPSILON AND TBK1 INHIBITORS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME TNIK, TNK1, NFKBIA KDR 1662/4885KCNMA1 1525/4885CSF1R 2206/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.